Vaccines and Therapeutic Approaches in Dermatological Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 308
Special Issue Editors
2. Department of Dermatology and Phlebology, Christian Hospital Unna, 59423 Unna, Germany
Interests: dermato-oncology; melanoma; immunotherapy; vaccination side effects; skin cancer; skin; psoriasis; clinical dermatology; basal cell carcinoma; squamous cell carcinoma; Merkel cell carcinoma
Special Issues, Collections and Topics in MDPI journals
2. Skin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
Interests: hidradenitis suppurativa; inflammation; hormones; Merkel cell carcinoma; melanoma; endocrinology; skin cancer; obesity
Special Issue Information
Dear Colleagues,
Vaccines are being investigated to treat and prevent skin diseases. Vaccines against solid tumors and skin cancer have recently seen increased development. In allergology, vaccines are also successfully used for hyposensitisation against certain allergens. Noninvasive dermal delivery systems make it easy to apply vaccines to different areas of the body. This method can impact clinical treatment due to many skin diseases with therapeutic targets. Currently, most clinical trials for therapies for skin disorders are conducted through intradermal injection. Combining noninvasive delivery techniques with specific vaccine formulation approaches can improve dermal delivery and achieve better therapeutic results. Recent efforts have been made to overcome the skin's barrier function using various smart delivery systems. By addressing these aspects and combining them with a deeper understanding of cell biology, we can improve the design of bioengineered materials to navigate the skin and enhance preventive and therapeutic outcomes.
This Special Issue aims to advance this field by providing a better understanding of how to safely and effectively deliver various vaccine types to target cells. The translational value of preclinical studies can be increased using human-relevant models or studies on human skin explants, tissue-engineered skin models, and human-based tissues grafted onto mice are welcome. We encourage all articles and reviews.
Prof. Dr. Thilo Gambichler
Guest Editor
Dr. Nessr Abu Rached
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccinations
- vaccines
- dermatology
- tumor therapy
- immune system
- side effects
- skin reactions
- virus vaccines
- virus
- bacteria
- COVID-19 vaccines
- mRNA
- vasculitis
- angioedema
- anaphylaxis
- thrombocytopenia
- B cells
- T cells
- vaccination complication
- safety
- target structures
